semaglutide poster Initiation in a Type 2 Diabetes Mellitus Post-Liver Transplant Patient Semaglutide - The New Wonder

If you missed a dose by fewer than 5 days, simply take it when you remember and resume your regular schedule

Recent evidence underscores its ability to reduce albuminuria, slow GFR decline, and provide CV protection, making it a valuable therapeutic option for CKD patients with and without DM

The 2025 KDIGO commentary highlights growing evidence that GLP-1RAs, particularly semaglutide, offer clinically meaningful kidney and CV protection in people with CKD, including those without DM

The paper also speaks directly to the lack of innovation in addiction medicine, which is the focus of CASPRs policy work: Since the FDA approval of the first AUD medication (disulfiram) in 1951, only 2 medications (naltrexone and acamprosate) have received subsequent FDA approval for AUD